Pharmaceutical companies in the Moscow region shipped products worth 260 billion rubles last year, according to the press service of the Ministry of Investment, Industry, and Science of the Moscow Region. In the first month of 2025, production increased by 11%.
According to Deputy Chairman of the Government — Minister of Investment, Industry, and Science of the Moscow Region, Ekaterina Zinovieva, the pharmaceutical sector is actively developing in 2025. In January, the production of medicines and medical materials increased by 11% compared to the same period last year. The region is home to 43 large and medium-sized enterprises producing medicines and medical materials, as well as 15 companies manufacturing medical equipment.
Among the rapidly growing companies, the deputy chairman highlighted "PSK Pharma," which operates in the special economic zone "Dubna." The company is expanding its production to meet the demand in the Russian market.
In the Khimki urban district, the group of companies "KhimRar" is implementing an investment project aimed at creating a production facility for pharmaceutical substances based on an existing enterprise. As part of the project, pharmaceutical components for Russian drugs will be produced, including "Aviandor," used for treating anxiety disorders, and "Elpid," used for HIV-infected patients.
Another special economic zone, "Big Serpukhov," is located in the Moscow Region. Among those who plan to establish production facilities there are enterprises from the pharmaceutical and medical industries. Investors are attracted by the proximity to major biotechnological and biochemical research centers.
The Moscow Region has created an environment conducive to the further development and expansion of the pharmaceutical and medical sectors. At the end of 2024, in the SEZ "Dubna," the company "Argumentum Pharma" completed the construction of a pharmaceutical complex for the production and development of medicines. The company "Integra-RUS" is implementing a project in the Istra urban district with investments of approximately 17 million rubles in a new production facility for oxygen concentrators. The facility is expected to be commissioned in 2026.
Source: PHARMMEDPROM
